Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL114 in Non-Hodgkin's Lymphoma
NCT05144347Phase 1Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of XL114 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma activated B-cell type (ABC-DLBCL), mantle cell lymphoma (MCL) and 2 more (2 arms), sponsored by Exelixis, Inc. Primary endpoints: Recommended Dose and/or Maximum Tolerated Dose and Objective Response Rate. Started Apr 2022; status: terminated.
02
Drugs
XL114
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma activated B-cell type (ABC-DLBCL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05144347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144347.